Literature DB >> 10188876

New semisynthetic vinca alkaloids: chemical, biochemical and cellular studies.

F Orosz1, B Comin, B Raïs, J Puigjaner, J Kovács, G Tárkányi, T Acs, T Keve, M Cascante, J Ovádi.   

Abstract

A new semisynthetic anti-tumour bis-indol compound, KAR-2 [3'-(beta-chloroethyl)-2',4'-dioxo-3,5'-spiro-oxazolidino-4-dea cetoxy-vinblastine] with lower toxicity than vinca alkaloids used in chemotherapy binds to calmodulin but, in contrast to vinblastine, does not exhibit anti-calmodulin activity. To investigate whether the modest chemical modification of bis-indol structure is responsible for the lack of anti-calmodulin potency and for the different pharmacological effects, new derivatives have been synthesized for comparative studies. The synthesis of the KAR derivatives are presented. The comparative studies showed that the spiro-oxazolidino ring and the substitution of a formyl group to a methyl one were responsible for the lack of anti-calmodulin activities. The new derivatives, similar to the mother compounds, inhibited the tubulin assembly in polymerization tests in vitro, however their inhibitory effect was highly dependent on the organization state of microtubules; bundled microtubules appeared to be resistant against the drugs. The maximal cytotoxic activities of KAR derivatives in in vivo mice hosting leukaemia P388 or Ehrlich ascites tumour cells appeared similar to that of vinblastine or vincristine, however significant prolongation of life span could be reached with KAR derivatives only after the administration of a single dose. These studies plus data obtained using a cultured human neuroblastoma cell line showed that KAR compounds displayed their cytotoxic activities at significantly higher concentrations than the mother compounds, although their antimicrotubular activities were similar in vitro. These data suggest that vinblastine/vincristine damage additional crucial cell functions, one of which could be related to calmodulin-mediated processes.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10188876      PMCID: PMC2362735          DOI: 10.1038/sj.bjc.6690218

Source DB:  PubMed          Journal:  Br J Cancer        ISSN: 0007-0920            Impact factor:   7.640


  26 in total

Review 1.  Effects of drugs on calmodulin-mediated enzymatic actions.

Authors:  J Ovádi
Journal:  Prog Drug Res       Date:  1989

2.  Dissimilar mechanisms of action of anticalmodulin drugs: quantitative analysis.

Authors:  F Orosz; M Telegdi; K Liliom; M Solti; D Korbonits; J Ovádi
Journal:  Mol Pharmacol       Date:  1990-12       Impact factor: 4.436

3.  Feasibility of drug screening with panels of human tumor cell lines using a microculture tetrazolium assay.

Authors:  M C Alley; D A Scudiero; A Monks; M L Hursey; M J Czerwinski; D L Fine; B J Abbott; J G Mayo; R H Shoemaker; M R Boyd
Journal:  Cancer Res       Date:  1988-02-01       Impact factor: 12.701

4.  Experimental antitumor activity of Navelbine.

Authors:  S Cros; M Wright; M Morimoto; H Lataste; J P Couzinier; A Krikorian
Journal:  Semin Oncol       Date:  1989-04       Impact factor: 4.929

5.  Influence of the guanine nucleotide phosphorylation state and of Mg2+ ions on the interaction of vinzolidine/tubulin 6 S: a fluorescence quenching study.

Authors:  F Codaccioni; M Dell'Amico; M Bourdeaux; C Briand; B Lux
Journal:  Arch Biochem Biophys       Date:  1988-11-15       Impact factor: 4.013

6.  Interaction of phosphofructokinase with tubulin and microtubules. Quantitative evaluation of the mutual effects.

Authors:  A Lehotzky; M Telegdi; K Liliom; J Ovádi
Journal:  J Biol Chem       Date:  1993-05-25       Impact factor: 5.157

7.  Ligand-modulated cross-bridging of microtubules by phosphofructokinase.

Authors:  A Lehotzky; Z Pálfia; J Kovács; A Molnár; J Ovádi
Journal:  Biochem Biophys Res Commun       Date:  1994-10-28       Impact factor: 3.575

8.  Interactions of tubulin with potent natural and synthetic analogs of the antimitotic agent combretastatin: a structure-activity study.

Authors:  C M Lin; S B Singh; P S Chu; R O Dempcy; J M Schmidt; G R Pettit; E Hamel
Journal:  Mol Pharmacol       Date:  1988-08       Impact factor: 4.436

9.  Binding of glyceraldehyde 3-phosphate dehydrogenase to microtubules.

Authors:  C Durrieu; F Bernier-Valentin; B Rousset
Journal:  Mol Cell Biochem       Date:  1987-03       Impact factor: 3.396

10.  Anti-calmodulin potency of indol alkaloids in in vitro systems.

Authors:  A Molnár; K Liliom; F Orosz; B G Vértessy; J Ovádi
Journal:  Eur J Pharmacol       Date:  1995-10-15       Impact factor: 4.432

View more
  3 in total

1.  Unexpected antitumorigenic effect of fenbendazole when combined with supplementary vitamins.

Authors:  Ping Gao; Chi V Dang; Julie Watson
Journal:  J Am Assoc Lab Anim Sci       Date:  2008-11       Impact factor: 1.232

Review 2.  Modifications on the basic skeletons of vinblastine and vincristine.

Authors:  Péter Keglevich; László Hazai; György Kalaus; Csaba Szántay
Journal:  Molecules       Date:  2012-05-18       Impact factor: 4.411

3.  Progress in the development of early diagnosis and a drug with unique pharmacology to improve cancer therapy.

Authors:  A Lehotzky; N Tokési; I Gonzalez-Alvarez; V Merino; M Bermejo; F Orosz; P Lau; G G Kovacs; J Ovádi
Journal:  Philos Trans A Math Phys Eng Sci       Date:  2008-10-13       Impact factor: 4.226

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.